MILLENNIUM NEWSROOM
Category
India's hiring landscape is shifting from degrees and tenure toward demonstrated skills, AI fluency, adaptability and practical experience as employers rethink recruitment.
India's clean energy transition is moving beyond renewable capacity additions, with grids, storage, manufacturing, financing and worker reskilling emerging as critical priorities.
India’s circular economy is gaining momentum across steel, cement, automobiles, batteries and bioenergy, but financing, logistics and regulatory gaps remain key challenges.
India's ethanol blending programme has delivered major foreign exchange and crude-oil savings, but consumers continue to pay ₹102.12 per litre for petrol in Delhi.
OneSource Specialty Pharma posted a strong start to FY27, reporting a 37% year-on-year increase in revenue and a 39% rise in EBITDA, driven by semaglutide commercialisation and new customer wins.
Industry leaders, policymakers and entrepreneurs at the Makhana Dialogue in Patna called for stronger market linkages, quality standards and policy support to position Indian Makhana as a globally competitive superfood.
Former finance journalist Suyash Maheshwari is helping professional services firms turn expertise into trust through FinBean Media, a newsroom-as-a-service platform designed for finance, consulting and advisory businesses.
Anadrone Systems and Kratos Defense & Security Solutions have signed a strategic agreement to jointly explore opportunities in India's expanding unmanned and autonomous defence systems market, supporting the country's modernization and Atmanirbhar Bharat objectives.
Indian companies are increasingly expanding overseas through acquisitions and greenfield investments as slowing domestic growth and strategic business priorities reshape investment decisions.
jUMPP has received IRDAI approval to distribute insurance products, marking its expansion into India’s growing digital insurance ecosystem.
Eris Lifesciences posted strong FY26 earnings with 11% growth in domestic formulations and a 37% EBITDA margin driven by diabetes and injectable portfolio expansion.